Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Photodermatol Photoimmunol Photomed ; 36(1): 29-33, 2020 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-31374130

RESUMEN

BACKGROUND: Erythropoietic protoporphyria (EPP) is a semi-dominantly inherited porphyria presenting with photosensitivity during early childhood. Acquired EPP has been reported; however, data regarding this rare disorder are scarce. PURPOSE: To evaluate the characteristics of acquired EPP. METHODS: A comprehensive search of PubMed, Google Scholar, ScienceDirect, and clinicaltrials.gov databases was performed by three reviewers. Studies describing patients with acquired EPP were included. Additionally, we present an index case of a 26-year-old patient who acquired clinically and biochemically typical EPP in association with myelodysplastic syndrome (MDS). RESULTS: We included 20 case reports describing 20 patients. Most (80%) patients were male of mean age 58 ± 13 years. In all patients, acquired EPP was associated with hematological disease, most commonly MDS (85%) followed by myeloproliferative disease (10%). In 86% of cases, hematological disease led to abnormality or somatic mutation in chromosome 18q (the locus of the ferrochelatase gene). The mean erythrocyte protoporphyrin IX concentration was very high (4286 µg/dL). Most (90%) patients presented with photosensitivity, 20% experienced blistering, and 25% presented with hepatic insufficiency, both uncommon in EPP. In 55% of patients, hematological disease was diagnosed after occurrence of cutaneous symptoms. Beta-carotene led to partial control of symptoms in 5 patients and resolution in another patient. Azacitidine treatment of MDS led to resolution of cutaneous symptoms in three patients. CONCLUSION: We present the distinct features of acquired EPP and highlight that any patient presenting with new-onset photosensitivity, irrespective of age should be evaluated for porphyria.


Asunto(s)
Azacitidina/uso terapéutico , Síndromes Mielodisplásicos , Trastornos por Fotosensibilidad , Protoporfiria Eritropoyética , beta Caroteno/uso terapéutico , Adulto , Anciano , Cromosomas Humanos Par 18/genética , Cromosomas Humanos Par 18/metabolismo , Eritrocitos/metabolismo , Femenino , Ferroquelatasa/genética , Ferroquelatasa/metabolismo , Sitios Genéticos , Humanos , Masculino , Persona de Mediana Edad , Mutación , Síndromes Mielodisplásicos/tratamiento farmacológico , Síndromes Mielodisplásicos/genética , Síndromes Mielodisplásicos/metabolismo , Trastornos por Fotosensibilidad/inducido químicamente , Trastornos por Fotosensibilidad/tratamiento farmacológico , Trastornos por Fotosensibilidad/genética , Trastornos por Fotosensibilidad/metabolismo , Protoporfiria Eritropoyética/inducido químicamente , Protoporfiria Eritropoyética/tratamiento farmacológico , Protoporfiria Eritropoyética/genética , Protoporfiria Eritropoyética/metabolismo , Protoporfirinas/genética , Protoporfirinas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA